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Purpose: The delivery of transgenes into human induced pluripotent stem cell (hiPSC)-derived 
cardiomyocytes (hiPSC-CMs) represents an important tool in cardiac regeneration with potential 
for clinical applications. Gene transfection is more difficult, however, for hiPSCs and hiPSC-CMs 
than for somatic cells. Despite improvements in transfection and transduction, the efficiency, 
cytotoxicity, safety, and cost of these methods remain unsatisfactory. The objective of this study is 
to examine gene transfection in hiPSCs and hiPSC-CMs using magnetic nanoparticles (NPs).
Methods: Magnetic NPs are unique transfection reagents that form complexes with nucleic 
acids by ionic interaction. The particles, loaded with nucleic acids, can be guided by a magnetic 
field to allow their concentration onto the surface of the cell membrane. Subsequent uptake of 
the loaded particles by the cells allows for high efficiency transfection of the cells with nucleic 
acids. We developed a new method using magnetic NPs to transfect hiPSCs and hiPSC-CMs. 
HiPSCs and hiPSC-CMs were cultured and analyzed using confocal microscopy, flow cytometry, 
and patch clamp recordings to quantify the transfection efficiency and cellular function.
Results: We compared the transfection efficiency of hiPSCs with that of human embryonic 
kidney (HEK 293) cells. We observed that the average efficiency in hiPSCs was 43%±2% com-
pared to 62%±4% in HEK 293 cells. Further analysis of the transfected hiPSCs showed that the 
differentiation of hiPSCs to hiPSC-CMs was not altered by NPs. Finally, robust transfection of 
hiPSC-CMs with an efficiency of 18%±2% was obtained.
Conclusion: The difficult-to-transfect hiPSCs and hiPSC-CMs were efficiently transfected 
using magnetic NPs. Our study offers a novel approach for transfection of hiPSCs and hiPSC-
CMs without the need for viral vector generation.
Keywords: human induced pluripotent stem cell-derived cardiomyocytes, therapy, pluripo-
tency, efficiency
Introduction
Human induced pluripotent stem cells (hiPSCs) are human somatic cells that are geneti-
cally reprogrammed into an embryonic-like, pluripotent state capable of differentiating 
into all three germ layers. Since the original description of induced pluripotent stem 
cells (iPSCs),1 the field has greatly expanded.2–4 The hiPSC technology has the poten-
tial to revolutionize regenerative and precision medicine by providing differentiated 
cells for cell-based therapy, disease modeling, drug testing, and high-throughput drug 
discovery in a patient-specific manner.
A large number of studies have refined the techniques for efficient directed- 
differentiation of hiPSCs into cardiomyocytes.5 In addition, multiple studies have 
provided evidence for the application of hiPSC-derived cardiomyocytes (hiPSC-CMs) 
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in cardiac transplantation in animal models.6 One of the main 
advantages of utilizing hiPSC-CMs, as opposed to undif-
ferentiated hiPSCs, is the elimination of the risk of teratoma 
formation. Moreover, hiPSC-CMs serve as an unlimited 
source of committed human cardiomyocytes.
Genetic modification of hiPSCs represents an essential 
tool for the study of hiPSCs. Expression of different markers 
is required in cell-based therapy applications of hiPSCs 
and hiPSC-CMs. With the advent of genome editing using 
CRISPR-Cas9 technology,7 it has become increasingly fea-
sible to correct disease-causing mutations in patient-specific 
hiPSCs, in order to create isogenic lines for disease modeling 
or potential therapeutics. However, there are significant 
technical challenges for the transfection of hiPSCs and 
hiPSC-CMs, since these cells are known to be difficult to 
transfect.8–10 Although multiple methods of genetic modi-
fications exist (ie, nucleofection, lipofectamine-mediated 
transfection, and viral-based transduction), their efficiency, 
cytotoxicity, safety, and cost remain unsatisfactory.8 Increas-
ingly, nanoparticles (NPs) have been used in biomedical 
research as powerful tools for drug delivery and personalized 
medicine.11 The objective of this study is to examine the 
efficiency of gene transfection in hiPSCs and hiPSC-CMs 
using magnetic NPs. Our study offers a novel approach to 
introduce desired genes into hiPSCs and hiPSC-CMs without 
the need for viral vector generation.
Materials and methods
cell culture
HiPSCs (19-9-7T and 6-9-9, WiCell, Madison, WI, USA) 
were plated in feeder-free conditions using matrigel-coated 
culture dishes and chemically defined medium, mTeSR™ 1 
(Stemcell Technologies, Inc., Cambridge, MA, USA). Cardiac 
myocytes were generated using a directed differentiation pro-
tocol.12 Briefly, differentiation of confluent (80%–90%) cells 
was initiated by adding RPMI/B27 medium (Thermo Fisher 
Scientific, Waltham, MA, USA) lacking insulin and contain-
ing the CHIR99021 (Tocris, Minneapolis, MN, USA) for 
24 hours, followed by RPMI/B27 media with an inhibitor of 
Wnt signaling, IWR-1-endo (Tocris). Differentiated hiPSCs 
were replated on a coverslip prior to transfection and action 
potential (AP) recordings.
Magnetic-assisted transfection using 
nanoparticles
The transfection was conducted following the manufacturer’s 
instructions (Neuromag, OZ Biosciences Inc., San Diego, 
CA, USA) and published methods.13,14 The NPs are posi-
tively charged, with a zeta .+30 mV in water. The size of 
the NPs ranges from 140 to 200 nm with the majority around 
160 nm, and the particle population is rather homogeneous. 
Briefly, plasmid DNAs (pIRES2-EGFP, Clontech Labora-
tories, Inc., Mountain View, CA, USA) or a double fusion 
construct (an integrating vector) with green fluorescence 
protein (GFP)15 were diluted in cell culture medium, and 
the NP reagent was added to the culture medium containing 
DNA. DNA handling followed NIH guidelines. After brief 
vortexing and 20-minute incubation at room temperature, the 
medium containing the DNA/nanoparticle complexes was 
added to the cell culture dish. The dish was then placed on a 
magnetic plate and incubated in a cell culture incubator for 
1, 2, and 4 hours. Cells were harvested or differentiated after 
24–48 hours of transfection. For comparison, lipofectamine-
2000 and -3000 (Thermo Fisher Scientific) were used.
Flow cytometric analysis
Cells were trypsinized and analyzed for GFP signal using 
a standard FACScan cytometer (BD Biosciences, San Jose, 
CA, USA), as we have described.16 Briefly, cells were fixed 
with 0.4% paraformaldehyde (PFA) before treating with 
anti-myosin heavy chain antibody (Developmental Studies 
Hybridoma Bank, Iowa city, IA, USA) in PBS with 5% 
donkey serum and 20 µg/mL DNAse-free RNAse (Sigma-
Aldrich Co., St Louis, MO, USA), overnight at 4°C. Cells 
were also stained with 40 µg/mL 7-amino-actinomycin D 
(7AAD, BD Biosciences) to measure the DNA content. 
Data were collected using a standard FACScan cytometer 
(BD Biosciences) upgraded to a dual laser system with the 
addition of a blue laser (15 mW at 488 nm) and a red laser 
(25 mW at 637 nm Cytek Development, Inc., Fremont, CA, 
USA). Data were acquired using CellQuest software (BD 
Biosciences) and analyzed using FlowJo software (Ver9.4 
Treestar Inc., San Carlos, CA, USA). Cells stained with 
isotype-matched IgG antibodies were used as controls to 
determine the positive cell population.
Immunofluorescence confocal 
microscopy
Expression of troponin T in hiPSC-CMs was detected by 
using mouse monoclonal anti-cardiac troponin T antibody 
(Abcam, Burlingame, CA, USA). Images were taken 
using Zeiss LSM 700 confocal microscope (Carl Zeiss, 
Oberkochen, Germany).
electrophysiologic recordings
Spontaneous action potentials (APs) of hiPSC-CMs were 
recorded using the perforated-patch recording technique 
at 35°C, as we have described.17 Briefly, the patch-pipettes 
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were backfilled with amphotericin (200 µg/mL). The pipette 
solution contained (mM) K-glutamate 120, KCl 25, MgCl
2
 
1, CaCl
2
 1, HEPES (N-2-hydroxyethylpiperazine-N’-2-
ethanesulphonic acid) 10, pH 7.4 with KOH. The external 
solution contained (in mM): NaCl 138, KCl 4, MgCl
2
 1, CaCl
2
 
2, NaH
2
PO
4
 0.33, glucose 10, HEPES 10, pH 7.4 with NaOH. 
The recording was performed using an Axopatch 200A 
amplifier (Molecular Devices, San Jose, CA, USA). The 
signal was filtered at 1 kHz using a 4-pole Bessel filter and 
digitized at sampling frequency of 2 kHz. Data analysis was 
carried out using Clampfit 10 software and graphics software 
(Origin Lab, Origin 6.0, Northampton, MA, USA).
statistical analysis
Data are presented as mean ± standard error (SE). Statistical 
comparisons were analyzed by Student’s t-test or one-
way ANOVA followed by Bonferroni tests for post hoc 
comparison. Statistical significance was considered to be 
achieved when P,0.05, and n represents the number of 
independently repeated experiments.
Results
Efficient transfection of hiPSCs using 
magnetic nanoparticles
NPs have recently been used as powerful tools for drug and 
gene delivery.11,18 Magnetic NPs have been successfully used 
for transfection of difficult-to-transfect primary neurons.13,14 
However, the use of magnetic NPs for transfection of hiPSCs 
remains unknown. We therefore tested the transfection of hiP-
SCs using magnetic nanoparticles. Figure 1A shows a diagram 
depicting magnet-assisted transfection (magnetotransfection) 
using NPs. A schematic representation of the experimental 
protocol is shown in Figure 1B. We first tested the double 
fusion construct, and the confocal microscopic images of 
transfected cells are shown in Figure 1C. Flow cytometric 
analyses were used to directly quantify nanoparticle-mediated 
transfection in HEK 293 cells and hiPSCs (Figure 1D and E). 
We further tested the transfection using a non-integrating GFP 
construct (pIRES2-EGFP) and optimized the time needed for 
magnetotransfection (Figure 1F and G). We note a significant 
increase in percentages of GFP-positive hiPSCs using 4 hours 
Figure 1 Transfection of hiPscs using magnetic nanoparticles.
Notes: (A) Diagram depicting magnetic nanoparticle-mediated transfection. (B) schematic representation of the experimental protocol. (C) confocal laser scanning 
microscopic images of double fusion construct-transfected HEK 293 cells (upper) and hiPSCs (lower). The left panels show the corresponding bright-field images of the cells. 
scale bar is 10 µm. (D) Flow cytometric analyses of transfection efficiencies. Magnetic nanoparticle-treated cells without GFP plasmids were used as control for background 
fluorescence (Background FL) shown in the left panel. GFP signals were detected from the GFP expression in the cells. (E) summary data from D (*P,0.05 by student’s t-test, 
n=3–7). (F) Flow cytometric analysis of pIres2-egFP-transfected hiPscs using 1, 2, and 4 hours of magnetotransfection. (G) summary data from F (*P,0.05 by aNOVa, 
n=3–7). pIRES2-EGFP vector has a lower transfection efficiency compared to double fusion construct (D and E) after 4 hours of magnetotransfection. (H) comparison of 
the transfection efficiency of hiPSCs using pIRES2-EGFP vector and lipofectamine-2000, -3000 and nanoparticle-mediated transfections. Four hours of transfection was used 
for all the conditions (*P,0.05 by aNOVa, n=3–7).
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of magnetotransfection. Importantly, there was a significant 
increase in the efficiency of transfection using magnetotransfec-
tion compared to lipofetamine-2000 and -3000 (Figure 1H).
Transfection with NPs did not alter the 
differentiation of hiPscs to hiPsc-cMs
One possible concern using magnetotransfection is whether 
the procedure may alter the differentiation efficiency of 
hiPSCs. Here, we directly compared the differentiation 
efficiency between control (non-transfected) and transfected 
hiPSCs into cardiomyocytes (CMs). The differentiated CMs 
exhibited large beating clusters with spontaneous firing APs, 
consistent with populations of ventricular-like, atrial-like, 
and nodal-like APs (Figure 2A and B).19 There were no sig-
nificant differences in the efficiency of differentiation into 
CMs between control hiPSCs and GFP-transfected hiPSCs 
using NPs (Figure 2C and D).
Magnetotransfection was more efficient 
than lipofectamine in hiPsc-cMs
HiPSCs can be differentiated into multiple cell types. 
HiPSC-CMs have potential for many applications in cardiac 
regeneration, as well as serving as models for cardiovascular 
diseases.6,20 HiPSC-CMs, as differentiated cells, are even 
more difficult to transfect compared to hiPSCs. It is critical 
to further evaluate the efficiency of magnetotransfection in 
hiPSC-CMs. By using flow cytometric analysis of both myo-
sin heavy chain (MyHC) and GFP positive cells, we directly 
demonstrated that magnetotransfection was more efficient 
than lipofectamine not only in hiPSCs, but also in hiPSC-
CMs (Figure 2E and F) using pIRES2-EGFP construct.
Discussion
Since the original description of iPSCs,1 the wide-reaching 
potentials of the technology have been rapidly realized for 
Figure 2 Transfection of hiPsc-cMs using magnetic nanoparticles.
Notes: (A) confocal laser scanning microscopic images of gFP-transfected hiPsc-cM. scale bar is 10 µm. (B) hiPSC-CMs exhibit spontaneous APs with ventricular-like, 
atrial-like, and nodal-like characteristics. The dotted line represents 0 mV. (C, D) Assessment of the efficiency of differentiation into CMs in control hiPSCs compared to 
hiPscs transfected with double fusion construct using nanoparticles by analysis of myosin heavy chain (Myhc) positive cells. summary data are shown in the right panels. 
(E, F) Comparison of the transfection efficiency in double positive hiPSC-CMs (MyHC+/gFP+) using pIres2-egFP vector and lipofectamine-2000, -3000, and nanoparticle-
mediated transfections. Data were collected 4 hours after transfection (*P,0.05 by aNOVa, n=3).
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both regenerative and precision medicine. The utilization of 
hiPSCs enables the development of an unlimited source of 
any human cell types needed for therapeutic and precision 
medicine. Genetic modification and expression of different 
reporters are essential for studies to evaluate cell-based 
therapy applications of hiPSCs and hiPSC-CMs. However, 
significant technical challenges exist for the transgene 
delivery into hiPSCs.8–10 Several methods have been devel-
oped for transgene delivery, which are mainly catogorized 
into viral and non-viral methods.8–10 Three types of viral 
vectors are widely used in the transgene delivery, including 
adenoviral, lentiviral, and adeno-associated viral vectors. 
The advantage of viral vectors lies in their high delivery 
efficacy, but their use also raises safety concerns including 
the cytotoxicity, cellular immune responses, and transgene 
integration into host genome. Non-viral methods, including 
mechanical and electrical methods such as injection or 
electroporation, and chemical methods such as lipofection, 
are potentially safer alternatives for transgene delivery into 
iPSCs, but the transfection efficiency is relatively lower.9,10 
For iPSC-CMs and embryonic stem cell-derived cardomyo-
cytes (ESC-CMs), viral transduction and nucleofection are 
commonly used for transgene delivery.21–24
Magnetic NPs have been used for the transfection of cell 
lines and primary cells including neurons.13,14,25 Magnetic 
nanoparticle-mediated gene transfer offers significant 
advantages over other gene transfer methods, such as high 
efficiency, low cytotoxicity, low cost, directional and distal 
controllability, efficient in vivo applications, and lack of 
immune responses.25–28 Recently, magnetic NPs have been 
used for gene delivery to neural precursor/stem cells.26,27,29 
However, whether magnetic nanoparticles can be efficiently 
used for transfection of iPSCs and iPSC-CMs has not been 
addressed and reported. Here, we demonstrate that the 
difficult-to-transfect hiPSCs and hiPSC-CMs can be effi-
ciently transfected using magnetic NPs.
Our study offers a novel approach to introduce trans-
genes into hiPSCs and hiPSC-CMs without the need for 
viral vector generation. Indeed, our findings transcend the 
benefits for hiPSCs and hiPSC-CMs. The technique may 
represent a non-viral method for the generation of hiPSCs 
and thus avoid the risk of genomic insertions inherent in 
some integrating viral methods. The potential application 
will be the genetic modification of hiPSCs and hiPSC-CMs 
for in vitro guided differentiation and in vivo transplantation 
for tissue regeneration and repair. The distal control of 
nanoparticles by a magnetic field will further potentiate the 
in vivo application and delivery of nucleic acids to specific 
organs for targeted gene therapy. The possible limitation 
may come from the cytotoxicity of magnetic NPs, which 
results from the accumulation of NPs in endosomes and/or 
vacuoles in cells. However, NPs will be degraded through 
normal iron metabolism over time, although the mechanism 
is still not well understood.11,25 For future studies, transfec-
tion efficiencies between different types of constructs need 
to be addressed.
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